Why are neuromelanin-containing dopaminergic neurons lost in idiopathic Parkinson's disease?
作者信息
Huenchuguala Sandro, Segura-Aguilar Juan
机构信息
Escuela de Tecnología Médica, Facultad de Salud, Universidad Santo Tomás, Los Carreras 753, Osorno, Chile.
Molecular and Clinical Pharmacology, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile.
出版信息
Cell Mol Life Sci. 2023 Sep 9;80(10):281. doi: 10.1007/s00018-023-04880-y.
Abstract
摘要
相似文献
1
Why are neuromelanin-containing dopaminergic neurons lost in idiopathic Parkinson's disease?
Cell Mol Life Sci. 2023 Sep 9;80(10):281. doi: 10.1007/s00018-023-04880-y.
2
Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
ACS Chem Neurosci. 2017 Apr 19;8(4):702-711. doi: 10.1021/acschemneuro.7b00034. Epub 2017 Mar 3.
3
Protective and toxic roles of dopamine in Parkinson's disease.
J Neurochem. 2014 Jun;129(6):898-915. doi: 10.1111/jnc.12686. Epub 2014 Mar 18.
4
The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
J Neural Transm (Vienna). 2023 May;130(5):611-625. doi: 10.1007/s00702-023-02617-6. Epub 2023 Mar 20.
5
Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase.
Antioxidants (Basel). 2022 Jan 31;11(2):296. doi: 10.3390/antiox11020296.
6
Single-neuron neurodegeneration as a degenerative model for Parkinson's disease.
Neural Regen Res. 2024 Mar;19(3):529-535. doi: 10.4103/1673-5374.380878.
7
The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Brain. 2021 Nov 29;144(10):3114-3125. doi: 10.1093/brain/awab191.
8
A Preclinical Model for Parkinson's Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies.
Antioxidants (Basel). 2023 Mar 9;12(3):673. doi: 10.3390/antiox12030673.
9
On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease.
Neural Regen Res. 2017 Jun;12(6):897-901. doi: 10.4103/1673-5374.208560.
10
Melanin and Neuromelanin: Linking Skin Pigmentation and Parkinson's Disease.
Mov Disord. 2023 Feb;38(2):185-195. doi: 10.1002/mds.29260. Epub 2022 Nov 9.
本文引用的文献
1
Neuromelanin magnetic resonance imaging of substantia nigra and locus coeruleus in Parkinson's disease with freezing of gait.
Front Aging Neurosci. 2023 Feb 2;15:1060935. doi: 10.3389/fnagi.2023.1060935. eCollection 2023.
2
The link between neuroinflammation and the neurovascular unit in synucleinopathies.
Sci Adv. 2023 Feb 15;9(7):eabq1141. doi: 10.1126/sciadv.abq1141.
3
Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase.
Antioxidants (Basel). 2022 Jan 31;11(2):296. doi: 10.3390/antiox11020296.
4
Astrocytes protect dopaminergic neurons against aminochrome neurotoxicity.
Neural Regen Res. 2022 Sep;17(9):1861-1866. doi: 10.4103/1673-5374.335690.
5
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson's Disease.
Aging Dis. 2021 Sep 1;12(6):1494-1515. doi: 10.14336/AD.2021.0527. eCollection 2021 Sep.
6
Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinson's disease.
Brief Bioinform. 2021 Jul 20;22(4). doi: 10.1093/bib/bbaa244.
7
Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease.
Front Aging Neurosci. 2016 Aug 22;8:196. doi: 10.3389/fnagi.2016.00196. eCollection 2016.
8
Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
J Comp Neurol. 2004 May 17;473(1):97-106. doi: 10.1002/cne.20098.
Zotero 插件